Immatics Financial Statements From 2010 to 2021

IMTX -  USA Stock  

USD 13.45  0.13  0.98%

Immatics financial statements provide useful quarterly and yearly information to potential Immatics NV investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immatics financial statements helps investors assess Immatics' valuation, profitability, and current liquidity needs.
Immatics NV does not presently have any fundamental trends for analysis.
.

Immatics Financial Statements 

 
Refresh
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics main balance sheet or income statement drivers, such as Gross Profit of 26.8 M, Interest Expense of 10.9 M or Net Income to Non Controlling Interests of 627.8 K, as well as many exotic indicators such as Asset Turnover of 0.17, Book Value per Share of 2.34 or Current Ratio of 3.58. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules. It can also supplement various Immatics Technical models. Please see the analysis of Immatics Correlation against competitors.

Immatics Revenues

26.77 MillionShare

Immatics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets220.9 M254.6 M96.8 M
Increasing
Slightly volatile
Cash and Equivalents176.8 M207.5 M70.2 M
Increasing
Slightly volatile
Investments24.6 M24.4 M17.4 M
Increasing
Slightly volatile
Investments Current24.6 M24.4 M17.4 M
Increasing
Slightly volatile
Deferred Revenue138.7 M132.1 M84.8 M
Increasing
Slightly volatile
Property Plant and Equipment Net12.4 M14 M5.9 M
Increasing
Slightly volatile
Trade and Non Trade Receivables1.2 M1.2 M575.3 K
Increasing
Slightly volatile
Trade and Non Trade Payables9.4 M10.1 M5.4 M
Increasing
Slightly volatile
Goodwill and Intangible Assets896.6 K914 KM
Decreasing
Slightly volatile
Total Liabilities155.6 M150.4 M93 M
Increasing
Slightly volatile
Shareholders Equity112.5 M104.3 M6.8 M
Increasing
Slightly volatile
Current Assets206.5 M239 M88.9 M
Increasing
Slightly volatile
Assets Non Current14.4 M15.7 M7.9 M
Increasing
Slightly volatile
Current Liabilities62.1 M60.6 M36.1 M
Increasing
Slightly volatile
Liabilities Non Current93.4 M89.8 M56.8 M
Increasing
Slightly volatile
Total DebtM6.2 M3.7 M
Increasing
Slightly volatile
Debt Current1.9 M1.9 M1.5 M
Increasing
Slightly volatile
Debt Non CurrentM4.3 M2.2 M
Increasing
Slightly volatile
Shareholders Equity USD137.2 M127.1 M9.1 M
Increasing
Slightly volatile
Cash and Equivalents USD213.2 M253.1 M82.5 M
Increasing
Slightly volatile
Total Debt USD7.2 M7.5 M4.3 M
Increasing
Slightly volatile

Immatics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues26.8 M31.3 M9.2 M
Increasing
Slightly volatile
Selling General and Administrative Expense28.3 M34.2 M11.9 M
Increasing
Slightly volatile
Research and Development Expense62.5 M67.1 M39.6 M
Increasing
Slightly volatile
Operating Expenses89.9 M101 M48.8 M
Increasing
Slightly volatile
Interest Expense10.9 M10.1 M1.9 M
Increasing
Slightly volatile
Net Income to Non Controlling Interests627.8 K557 K858.3 K
Decreasing
Slightly volatile
Weighted Average Shares47.3 M48 M35.5 M
Increasing
Slightly volatile
Weighted Average Shares Diluted47.3 M48 M35.5 M
Increasing
Slightly volatile
Revenues USD32.3 M38.1 M10.8 M
Increasing
Slightly volatile
Gross Profit26.8 M31.3 M9.2 M
Increasing
Slightly volatile

Immatics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing224.3 M207.9 M53.6 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares201.8 M250.6 M73.6 M
Increasing
Slightly volatile
Net Cash Flow from Operations(87.9 M)(85.6 M)M
Decreasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (2.2 M)(2.1 M)(267 K)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents94.8 M106.3 M45.2 M
Increasing
Slightly volatile
Share Based Compensation20.1 M18.6 M4.4 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion4.3 M4.4 M2.7 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity(5.8)(5.657)2.7758
Decreasing
Slightly volatile
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Asset Turnover0.170.160.1428
Increasing
Slightly volatile
Enterprise Value over EBITDA0.320.291(6.7967)
Increasing
Slightly volatile
Sales per Share0.720.7940.2764
Increasing
Slightly volatile
Price to Sales Ratio13.9513.58959.8105
Decreasing
Slightly volatile
Price to Book Value1.641.525(11.1078)
Increasing
Slightly volatile
Debt to Equity Ratio1.561.443(5.1782)
Increasing
Slightly volatile
Current Ratio3.583.9432.321
Increasing
Slightly volatile
Free Cash Flow per Share(1.99)(1.94)0.3056
Decreasing
Slightly volatile
Book Value per Share2.342.1720.0353
Increasing
Slightly volatile
Tangible Assets Book Value per Share4.935.2862.5526
Increasing
Slightly volatile

Immatics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization209.5 M193.9 M181.3 M
Increasing
Slightly volatile
Enterprise Value(78.2 M)(76.2 M)214.9 M
Decreasing
Slightly volatile
Average Equity43.7 M40.5 M1.1 M
Increasing
Slightly volatile
Average Assets198.3 M195.4 M144.6 M
Increasing
Slightly volatile
Invested Capital Average11 M10.7 M77.5 M
Decreasing
Slightly volatile
Tangible Asset Value219.9 M253.7 M95.8 M
Increasing
Slightly volatile
Free Cash Flow(95.6 M)(93.1 M)5.2 M
Decreasing
Slightly volatile
Working Capital144.4 M178.4 M52.8 M
Increasing
Slightly volatile

Immatics Fundamental Market Drivers

Short Percent Of Float4.14%
Forward Price Earnings-7.22
Shares Short Prior Month1.86M
Average Daily Volume Last 10 Day123.51k
Average Daily Volume In Three Month127.88k
Date Short Interest28th of May 2021
Fifty Day Average13.78
Two Hundred Day Average12.36

Immatics Upcoming Events

Upcoming Quarterly Report1st of December 2021
Next Earnings Report29th of March 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Immatics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immatics income statement, its balance sheet, and the statement of cash flows. Immatics investors use historical funamental indicators, such as Immatics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immatics investors may use each financial statement separately, they are all related. The changes in Immatics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immatics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immatics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Deferred Revenue132.1 M138.7 M
Revenues31.3 M26.8 M
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications Amgen Inc. and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 285 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immatics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now

   

Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immatics Correlation against competitors. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.